GR-159897

GR-159897 is a drug that acts as a selective, non-peptide antagonist at the neurokinin 1 receptor. It was developed by GlaxoSmithKline and has been researched for various applications such as the treatment of anxiety, depression, nausea, and emesis (vomiting), but was not successful in clinical trials and has not been adopted for medical use.

Pharmacology[edit | edit source]

GR-159897 is a potent and selective antagonist for the neurokinin 1 (NK1) receptor. The NK1 receptor is a G protein-coupled receptor located in the central and peripheral nervous system, which is activated by the neuropeptide substance P. Antagonism of this receptor by GR-159897 can potentially modulate the effects of substance P, which is involved in pain perception, stress, and emesis.

Clinical Trials[edit | edit source]

GR-159897 has been investigated in clinical trials for its potential therapeutic effects in various conditions. However, it did not show significant efficacy in these trials and has not been approved for medical use.

Anxiety and Depression[edit | edit source]

In preclinical studies, GR-159897 showed potential as a treatment for anxiety and depression. However, in clinical trials, it did not demonstrate significant efficacy compared to placebo.

Nausea and Emesis[edit | edit source]

GR-159897 has also been studied for its potential to treat nausea and emesis, due to the role of the NK1 receptor in these conditions. However, it did not show significant efficacy in clinical trials.

Development[edit | edit source]

GR-159897 was developed by the pharmaceutical company GlaxoSmithKline. Despite its lack of success in clinical trials, research into NK1 receptor antagonists continues, due to the potential therapeutic applications of modulating this receptor.

See Also[edit | edit source]

GR-159897 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.